Skip to content

Biohaven BHVN Enterprise value

Enterprise value at other companies

Eli Lilly logo
Eli LillyLLY
$859.77B+10.6%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$5.01B+104%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$1.43B+352%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$1.24B+102%
uniQure logo
uniQureQURE
$945.68M+124%
Roivant Sciences logo
Roivant SciencesROIV
$18.51B+157%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.23B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Calculated from Biohaven’s reported figures.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's enterprise value?
Biohaven (BHVN) reported enterprise value of $1.28B in Q1 2026.
How has Biohaven's enterprise value changed year-over-year?
Biohaven's enterprise value decreased by 46.3% year-over-year, from $2.39B to $1.28B.
What is the long-term trend for Biohaven's enterprise value?
Over 3 years (2022 to 2025), Biohaven's enterprise value has grown at a 28.1% compound annual growth rate (CAGR), from $737.07M to $1.55B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.